CTLT - Catalent Profit before interest, taxes and amortization

Graphic logo of catalent.com (CTLT)

The stability of Catalent, Inc. (CTLT) is based on global vaccine production, however, current operating profit in cash on GURU.Markets reflects volatility, where the value of reflects this status. Risks are mitigated by the dependence on external raw material suppliers and a complex asset integration process following the acquisition by the Danish holding company, which temporarily limits new merger and acquisition deals.

Operating profit before deduction of amortization: Catalent Inc. (CTLT) for 07/04/2022 - 11/10/2026

Catalent (CTLT) - metric breakdowns and financial figures

- current price and projected stock value:
Price Catalent, Inc|CTLT - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Catalent|CTLT - Total Company Value
- book capitalization data:
Net Assets per Share Catalent|CTLT - Company Net Assets|Market Cap to Book Value Multiple catalent.com|CTLT - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Catalent, Inc.|CTLT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Catalent Inc.|CTLT - Company Aggregate Debts|Debts to Book Capitalization Catalent|CTLT - Company Long-Term Liabilities|Amount of Current Liabilities Catalent|Quick Ratio catalent.com
- company profitability and valuation multiples indicators:
CTLT - Company Net Income|Expected Profit Catalent, Inc.|CTLT - P/E Multiple|Projected Price to Earnings Ratio catalent.com|CTLT - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Catalent|CTLT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Catalent|CTLT - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months catalent.com|CTLT - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Catalent, Inc.
Summary company analytics:CTLT (Catalent, Inc)
Signature product of Catalent Pharma Solutions

Catalent, Inc. revenues depend directly on the volume of CDMO contracts for the production of vaccines and biologics for global pharmaceutical corporations. This absolute operating profit accumulates daily net cash flows from core operations, allowing investors to determine the true direction of the long-term trend through this metric's dynamics and avoid entering the asset at its valuation peak.

Competitor analysis for Catalent, Inc.

Company profit before taxes, interest and amortization IQV (Quintiles)|Labcorp Holdings Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization medpace.com|ICON Plc (ICLR) - Profit before payment of interest, taxes and amortization|CRL - Operating income before deduction of amortization|Operating profit before deduction of amortization EVO|FTRE (Fortrea Clinical) - Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization Lifecore Biomedical (LFCR)|Operating income before deduction of amortization omniab.com|Operating profit EBITDA NOTV (Inotiv)|CDMO - Operating profit before deduction of amortization|NightHawk Biosciences - Operating profit EBITDA